GT
TAK icon

Glenmede Trust’s Takeda Pharmaceutical TAK Stock Holding History

Glenmede Trust’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$461K Sell
28,770
-1,435
-5% -$23.7K ﹤0.01% 1016
2026
Q1 		$559K Buy
30,205
+2,640
+10% +$46.3K ﹤0.01% 926
2025
Q4 		$430K Buy
+27,565
New +$394K ﹤0.01% 1002
2025
Q1 		$366K Buy
24,580
+13,569
+123% +$190K ﹤0.01% 1011
2024
Q4 		$146K Buy
11,011
+819
+8% +$11.3K ﹤0.01% 1275
2024
Q3 		$145K Sell
10,192
-6,307
-38% -$89.5K ﹤0.01% 1266
2024
Q2 		$213K Sell
16,499
-2,230
-12% -$29.5K ﹤0.01% 1176
2024
Q1 		$260K Buy
18,729
+13
+0.1% +$189 ﹤0.01% 1097
2023
Q4 		$267K Buy
18,716
+7,458
+66% +$106K ﹤0.01% 1067
2023
Q3 		$174K Sell
11,258
-6,445
-36% -$99.8K ﹤0.01% 1114
2023
Q2 		$292K Hold
17,703
– – ﹤0.01% 998
2023
Q1 		$292K Buy
17,703
+4,175
+31% +$66.5K ﹤0.01% 1003
2022
Q4 		$211K Sell
13,528
-2,426
-15% -$33.9K ﹤0.01% 1085
2022
Q3 		$206K Sell
15,954
-382
-2% -$5.31K ﹤0.01% 1082
2022
Q2 		$228K Sell
16,336
-1,579
-9% -$22.5K ﹤0.01% 1071
2022
Q1 		$255K Buy
17,915
+601
+3% +$8.82K ﹤0.01% 1076
2021
Q4 		$235K Sell
17,314
-6,412
-27% -$89.9K ﹤0.01% 1107
2021
Q3 		$387K Buy
23,726
+989
+4% +$16.6K ﹤0.01% 966
2021
Q2 		$381K Buy
22,737
+8,824
+63% +$150K ﹤0.01% 957
2021
Q1 		$253K Buy
+13,913
New +$250K ﹤0.01% 1015
2020
Q4 		– Sell
-10,169
Closed -$181K – 2136
2020
Q3 		$181K Buy
10,169
+1,589
+19% +$28.9K ﹤0.01% 1042
2020
Q2 		$153K Sell
8,580
-2,170
-20% -$39K ﹤0.01% 1068
2020
Q1 		$211K Hold
10,750
– – ﹤0.01% 1179
2019
Q4 		$211K Buy
10,750
+480
+5% +$9.18K ﹤0.01% 1179
2019
Q3 		$175K Sell
10,270
-50
-0.5% -$865 ﹤0.01% 1224
2019
Q2 		$181K Sell
10,320
-219,114
-96% -$3.99M ﹤0.01% 1192
2019
Q1 		$4.67M Buy
229,434
+11,349
+5% +$228K 0.02% 484
2018
Q4 		$3.67M Buy
+218,085
New +$3.68M 0.02% 508

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Glenmede Trust's TAK Position: Q2 2026 in Review

Glenmede Trust reduced its Takeda Pharmaceutical (TAK) stake by 4.8% in Q2 2026, selling an estimated $23.7K and leaving 28,770 shares worth $461K. The position accounts for ﹤0.01% of the portfolio, ranked #1016.

Glenmede Trust first reported a position in TAK in Q4 2018 and has held it in 28 quarters since. The position peaked at $4.67M in Q1 2019. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Glenmede Trust held 28,770 shares of Takeda Pharmaceutical worth $461K as of Q2 2026.
  • Glenmede Trust sold 1,435 Takeda Pharmaceutical shares in Q2 2026, an estimated $23.7K.
  • Takeda Pharmaceutical made up ﹤0.01% of Glenmede Trust's portfolio in Q2 2026, its #1016 holding.
  • Glenmede Trust first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 28 quarters since.
  • Glenmede Trust's Takeda Pharmaceutical position peaked at $4.67M in Q1 2019.
  • 376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.